Meropenem(SM—7338)是一个研究中的碳青霉稀类抗生素,对某些革兰氏阴性杆菌的抗菌活性较Imipenem强,对肾脱氢肽酶比较稳定。在本研究中我们试图评价Me—ropenem、lmipenem及另外几种β—内酰胺、环丙沙星和庆大霉素,对一组抗生素耐药菌及罕见的革兰氏阴性杆菌抗菌活性。本研究以临床分离的病原菌作为实验菌株,因为它们显示对几种β—内酰胺(例如,若干肠杆菌科菌和绿脓杆菌)、氨基糖苷类和喹诺酮类的耐药性,或者因为它们代表医院内虚弱病人感染的一类常见的需氧革兰氏阴性杆 Meropenem (SM-7338) is a carbapenem-based antibiotic that has been studied and shows greater antibacterial activity against certain Gram-negative bacilli than Imipenem and is relatively stable against renal dehydropeptidase. In this study we attempted to evaluate the antibacterial activity of Me-ropenem, lmipenem and several other β-lactams, ciprofloxacin and gentamicin against a panel of antibiotic-resistant and rare Gram-negative bacilli. The present study uses clinically isolated pathogens as experimental strains because they show resistance to several beta-lactams (eg several Enterobacteriaceae and Pseudomonas aeruginosa), aminoglycosides and quinolones, or because they represent A class of common aerobic Gram-negative rods infected with weak patients in hospitals